New Study Validates Signatera™ in Endometrial Cancer
Go back to New Study Validates Signatera™ in Endometrial Cancer| (NASDAQ: NTRA) | Delayed: 400.30 +9.51 (2.43%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $390.79 | 52 Week High | $13.80 | |||
| Open | $392.90 | 52 Week Low | $6.52 | |||
| Day High | $407.06 | P/E | N/A | |||
| Day Low | $391.51 | EPS | $0.00 | |||
| Volume | 512,350 | |||||



